| Document |
Document Title |
|
WO/2024/071565A1 |
An electronic device, according to one embodiment, may comprise: a cartridge receiving part that receives a cartridge containing an emulsion therein; a shredding circuit that includes a shredding element capable of shredding at least a p...
|
|
WO/2024/073715A2 |
Described herein are gene-targeted therapies and compositions that can include a vessel-specific viral vector, preferably in combination with a HDAC9-derived promoter to transduce SMC and deliver a base editor that corrects mutant allele...
|
|
WO/2024/071538A1 |
The present invention relates to a novel benzoxazole derivative comprising 4-amino-butanamide and an anti-inflammatory use thereof.
|
|
WO/2024/071336A1 |
The present invention relates to a bacterial exopolysaccharide having a repeating structure comprising a series of repeating units represented by formula (I), and to the use of the bacterial exopolysaccharide for immunopotentiation. (In ...
|
|
WO/2024/067465A1 |
Provided are a compound useful as a KIF18A inhibitor, a pharmaceutically acceptable salt, an ester or a stereoisomer thereof, a pharmaceutical composition and a preparation comprising the compound or the pharmaceutically acceptable salt,...
|
|
WO/2024/067773A1 |
Provided herein are compounds and methods for modulating or inhibiting TEAD. Further provided herein are pharmaceutical compositions comprising the TEAD inhibitors and methods of treatment using the TEAD inhibitors or the pharmaceutical ...
|
|
WO/2024/067784A1 |
Provided are an amorphous form and 16 crystal forms of a compound represented by formula (I). The crystal forms are named in order from crystal form A to crystal form P. Also provided is a preparation method for the amorphous form and po...
|
|
WO/2024/067675A1 |
The present invention provides a compound represented by formula (I), a pharmaceutical composition, and a preparation method therefor and use thereof. The compound has a good inhibitory effect on KIF18A, and can be used alone or in a bin...
|
|
WO/2024/069507A1 |
This invention relates to novel processes for synthesizing N-(3-(6-Amino-5-(2-(N- methylacrylamido)ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphe
nyl)-4-cyclopropyl-2-fluorobenzamide and to intermediates which are used in such processes.
|
|
WO/2024/073658A1 |
The subject matter described herein is directed to myelin-promoting compounds of Formula (I) and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of admin...
|
|
WO/2024/071439A1 |
The present invention provides a novel compound that has an STAT6 inhibitory effect and is efficacious in treating inflammatory diseases and allergic diseases such as atopic dermatitis. A compound represented by general formula (I) and h...
|
|
WO/2024/066981A1 |
Provided in the present invention are deuterated pyrazole derivatives, of which the structures are represented as formula (I). Further disclosed in the present invention are pharmaceutically acceptable salts and stereoisomers of the deri...
|
|
WO/2024/067818A1 |
The present disclosure relates to a chimeric compound used for targeted degradation of a BCL-2 protein, a preparation method therefor, and pharmaceutical application thereof. Specifically, the present disclosure relates to a heterocyclic...
|
|
WO/2024/067576A1 |
Provided in the present invention is the use of bilobalide in the preparation of a drug for preventing or treating diabetes and diabetic complications.
|
|
WO/2024/071349A1 |
The present disclosure provides a suspension-type ophthalmic solution having excellent re-dispersibility. More specifically, the present disclosure provides a water-based suspension preparation containing a first component and a second c...
|
|
WO/2024/069378A1 |
The present invention provides novel compounds of Formula (I) or its pharmaceutically acceptable salts. The novel compounds reported in present invention are suitable for the treatment against infection caused by Gram-positive bacteria.
|
|
WO/2024/072995A1 |
Provided herein is a composition for regenerating and rejuvenating a mammalian tissue in vivo. In some embodiments, the composition may comprise L-methionine, threonine, glycine, putrescine, cysteine and S-adenosylmethionine (SAM) in amo...
|
|
WO/2024/065907A1 |
Provided are a pentacyclic triterpene saponin derivative, a preparation method therefor, and a use thereof. A compound A3 is used as a raw material, a derivative is prepared by targeting a carboxyl group of C-28 and using an esterificati...
|
|
WO/2024/071348A1 |
The present disclosure provides a suspension ophthalmic solution having exceptional re-dispersibility. More specifically, the present disclosure provides an aqueous suspension containing heat-treated (E)-2-(7-trifluoromethylchroman-4-yld...
|
|
WO/2024/066984A1 |
Provided in the present invention is a tricyclic derivative, and the structure thereof is as shown in formula (I). In addition, further disclosed in the present invention are a pharmaceutically acceptable salt of the derivative, a stereo...
|
|
WO/2024/071138A1 |
The purpose of the present invention is to provide a novel mitochondrial function improving composition. The present invention provides a mitochondrial function improving composition including, as an active ingredient, a fat that contain...
|
|
WO/2024/072178A1 |
The present invention relates to a compound for targeted protein degradation and a use thereof, and more specifically, the compound according to the present invention degrades epidermal growth factor receptor (EGFR) mutant proteins, and ...
|
|
WO/2024/068976A1 |
The present invention relates to new compounds capable of inhibiting the activity of SHP2 phosphatase. Compounds of the invention can be used for the treatment of disorders associated with SHP2 deregulation. The present invention also re...
|
|
WO/2024/073356A1 |
The disclosure relates to 2-[2-ethoxy-4-(ethylsulfanyl)-5-methoxyphenyl]ethan-1-aminiu
m chloride (2-(2-ethoxy-4-(ethylthio)-5-methoxyphenyl)ethan-1-a minium chloride), crystalline 2-(2-ethoxy-4-(ethylthio)-5-methoxyphenyl)ethan-1-aminiu...
|
|
WO/2024/072108A1 |
The present invention relates to a novel crystalline form of enavogliflozin, and a preparation method therefor. The novel crystalline form of enavogliflozin, according to the present invention, has thermodynamic stability and a hygroscop...
|
|
WO/2024/067445A1 |
Provided are a compound of formula (I) having inhibitory activity for protein arginine methyltransferase 5, and a method for synthesis and use of the compound.
|
|
WO/2024/073473A1 |
Provided herein are methods of treating non-hemorrhagic closed head injury (NHCHI) with 3,3'-diindolylmethane or an analog thereof. In one embodiment, NHCHI covers Traumatic Brain Injuries (TBIs) including mild to severe concussion, blas...
|
|
WO/2024/068153A1 |
This application relates generally to the field of treatment or prevention of "open" vascular surgical interventions with administration of a macrocyclic triene immunosuppressive compound in order to reduce or eliminate stenotic and/or v...
|
|
WO/2024/067500A1 |
Provided is an antisense nucleic acid glycosyl conjugate, which is formed by covalently conjugating a sugar molecule to the 5' end of an antisense nucleic acid by means of a linker arm. In-vitro pharmacodynamics show that the anti-tumor ...
|
|
WO/2024/073680A1 |
Described herein are novel piperidine urea derived compounds and their pharmaceutical compositions for the treatment of neurodegenerative disorders and diseases mediated by soluble epoxide hydrolase.
|
|
WO/2024/068159A1 |
This application relates generally to the field of synthesis, formulations and perivascular treatment methods involving cyclic ester derivatives of everolimus.
|
|
WO/2024/072075A1 |
The present invention relates to a pharmaceutical composition for preventing and treating cancers, including lung cancer, caused by abnormal cell growth, the composition containing, as active ingredients, a novel trisubstituted pyrimidin...
|
|
WO/2024/066080A1 |
An arsenic compound-based tumor vaccine, a preparation method therefor, and an application thereof. The arsenic compound-based tumor vaccine comprises tumor cells treated by an arsenic compound, may activate an anti-tumor immune response...
|
|
WO/2024/073709A2 |
The technology described herein relates modified oligonucleotides and double-stranded RNAs, e.g., siRNAs, compositions and kits comprising them and methods of their use for inhibiting target genes.
|
|
WO/2024/070172A1 |
Provided are an exceptional agent and method for inducing differentiation from dental pulp cells into odontoblasts. Also provided are an exceptional pharmaceutical composition and pulp capping agent for dentin regeneration. This agent fo...
|
|
WO/2019/043596A9 |
The present invention relates to compositions providing improved substantivity, comfort and/or feel to the eye upon application. The present invention further relates to compositions comprising a cellulose derivative in combination with ...
|
|
WO/2024/073056A1 |
A pharmaceutical formulation for treating a patient with an elevated serum level of an intestinal microbial metabolite includes an effective amount of cucurbituril. A method of treating a patient with an elevated serum level of an intest...
|
|
WO/2024/067820A1 |
Provided are novel tricyclic compounds as CDK inhibitors, which are useful for treating diseases or conditions mediated by CDKs, particularly cancers and other diseases caused by abnormal cell proliferation. Preparation methods, pharmace...
|
|
WO/2024/067812A1 |
The present invention relates to an aromatic acetylene derivative, a preparation method therefor, and a medical use of a pharmaceutical composition containing said derivative. Specifically, the present invention relates to an aromatic ac...
|
|
WO/2024/073672A1 |
The present disclosure relates to methods of treating a kidney disease or disorder, including methods comprising administering sparsentan and a SGLT2 inhibitor to a subject in need thereof.
|
|
WO/2024/073114A1 |
The present disclosure relates to compositions of matter and methods used to activate effector nucleic acids and effector targets in vivo via a CRISPR-based cascade system. The compositions and methods achieve non-specific delivery of ca...
|
|
WO/2024/067631A1 |
Use of a composition of an FAK inhibitor, a substance for inducing immunogenic cell death, and an immune checkpoint inhibitor in preparing a drug for treating a tumor. The substance for inducing immunogenic cell death is an RNA polymeras...
|
|
WO/2024/069144A1 |
The invention provides means and methods for treating, preventing or reversing retinal degeneration by RNA editing. The methods comprise administering to the subject a vector or a pair of complementary vectors that express a dCaslS-ADARn...
|
|
WO/2024/068758A1 |
The present invention relates to an orodispersible formulation of vortioxetine comprising a granular component comprising vortioxetine or a salt thereof together with an inert carrier; a polymeric component; and an extragranular matrix w...
|
|
WO/2024/072793A1 |
The invention provides pyridine carboxamide compounds, pharmaceutical compositions, and their use in treating medical conditions.
|
|
WO/2024/068699A1 |
This invention concerns pharmaceutical compositions for administration via intramuscular or subcutaneous injection, comprising micro-particles of the anti-TB compound bedaquiline, suspended in an aqueous pharmaceutically acceptable carri...
|
|
WO/2024/067542A1 |
The present invention relates to a spirocyclic derivative-containing salt or crystal form, and a preparation method therefor and a use thereof. Particularly, the present invention relates to a salt or crystal form of a compound (R)-1-(4'...
|
|
WO/2024/071720A1 |
The present invention relates to a pharmaceutical composition for preventing or treating periodontitis, and an anti-inflammatory composition, the compositions comprising lipoteichoic acid or a pharmaceutically acceptable salt thereof. Th...
|
|
WO/2024/069589A1 |
Hexahydrocannabinol (HHC), hexahydrocannabidiol (H4CBD), and hexahydrocannabidivarin (H4CBDV) derivatives are disclosed. Also disclosed are pharmaceutical compositions comprising such derivatives. Further described are methods of use the...
|
|
WO/2024/069644A1 |
The present invention relates to a pharmaceutical acceptable ferric carboxymaltose with better characterisation for bio-available iron and process for preparation thereof. The process comprises a controlled oxidation step to minimize ran...
|
